Inhibikase Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.8%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$214.3Knext fiscal year
FY EPS (est.)
-$0.37next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release (Quarter Ended September 30, 2026) | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly170.4MTarget: Sufficient liquidity to fund operations for at least 12 months
IMPROVE-PAH Phase 3 Trial Patient Enrollment (Part A) Quarterly1.0
IMPROVE-PAH Phase 3 Trial Global Clinical Sites Activated QuarterlyTarget: Up to approximately 180 sites globally
IMPROVE-PAH Phase 3 Trial Country Approvals Monthly16.0Target: Over 25 countries
Watch Items
- IMPROVE-PAH Phase 3 Trial Part A Topline Data ReadoutTrigger: Completion of 24-week Pulmonary Vascular Resistance (PVR) assessment for 140 patientsAction: Evaluate efficacy and safety profile to support seamless transition and sample size adjustments for Part B
- FDA Decision on Orphan Drug Designation (ODD) Application for IKT-001 in PAHTrigger: Receipt of official written response or designation from the U.S. FDAAction: Update market and adjust commercialization and regulatory strategy to leverage 7-year market exclusivity benefits
- Strategic Options and Out-Licensing Milestones for Risvodetinib (IkT-148009)Trigger: Execution of clinical development milestones by partner ABLi Therapeutics or new strategic transactionsAction: Monitor partner compliance and recognize potential milestone payments up to $47.5 million
Research as of 20 Jun 2026